Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| InflaRx NV | IFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 3.29 | 0.00 | 0.00 | 0.00 | 3.29 | 03:59:39 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.83 | 3.38 | 0.55 | 16.27% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
InflaRx NV Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 85.89M | 26.11M | $ -29.82M | -1.37 | - | 26.11M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
InflaRx NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.56 | 3.7001 | 3.04 | 3.29 | 479,926 | -0.27 | -7.58% |
| 1 Month | 2.63 | 3.7001 | 2.26 | 3.14 | 977,868 | 0.66 | 25.1% |
| 3 Months | 3.08 | 3.88 | 2.17 | 2.88 | 607,202 | 0.21 | 6.82% |
| 6 Months | 3.31 | 3.88 | 2.17 | 3.03 | 835,039 | -0.02 | -0.6% |
| 1 Year | 29.99 | 53.10 | 2.17 | 7.28 | 719,966 | -26.70 | -89.03% |
| 3 Years | 15.19 | 53.10 | 2.17 | 8.68 | 372,843 | -11.90 | -78.34% |
| 5 Years | 15.19 | 53.10 | 2.17 | 8.68 | 372,843 | -11.90 | -78.34% |
InflaRx NV Description
| InflaRx NV is a clinical-stage biopharmaceutical company is focused on applying proprietary anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. The lead product candidate of the company is IFX-1, which is developed for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The company's proprietary anti-C5a technology is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. It is also developing IFX-1 for the treatment of AAV, a life-threatening autoimmune disease associated with powerful inflammatory flares that impair kidney function and lead to fatal organ dysfunction. |
